McNamara et al. [123] generated covalently linked aptamer–siRNA chimeric molecules to specifically deliver therapeutic siRNAs targeting PLK1 and BCL2 (two survival genes that are overexpressed in most human cancers) mRNAs into prostate cancer cells expressing the surface receptor PSMA. This evidence concerns the gene FOLH1 and prostate cancer.